MDT

100.99

-0.45%↓

A

134.88

-2.69%↓

VEEV

221.76

-1.44%↓

HQY

84.14

-2.65%↓

NEOG

9.81

-1.21%↓

MDT

100.99

-0.45%↓

A

134.88

-2.69%↓

VEEV

221.76

-1.44%↓

HQY

84.14

-2.65%↓

NEOG

9.81

-1.21%↓

MDT

100.99

-0.45%↓

A

134.88

-2.69%↓

VEEV

221.76

-1.44%↓

HQY

84.14

-2.65%↓

NEOG

9.81

-1.21%↓

MDT

100.99

-0.45%↓

A

134.88

-2.69%↓

VEEV

221.76

-1.44%↓

HQY

84.14

-2.65%↓

NEOG

9.81

-1.21%↓

MDT

100.99

-0.45%↓

A

134.88

-2.69%↓

VEEV

221.76

-1.44%↓

HQY

84.14

-2.65%↓

NEOG

9.81

-1.21%↓

Search

Quidel Corp

Fermé

28.1 -7.72

Résumé

Variation du prix de l'action

24h

Actuel

Min

28

Max

30.49

Chiffres clés

By Trading Economics

Employés

6,600

Recommandations

By TipRanks

Recommandations

Neutre

Prévisions sur 12 Mois

-3.13% downside

Dividendes

By Dow Jones

Prochains Résultats

11 févr. 2026

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

277M

1.9B

Ouverture précédente

35.82

Clôture précédente

28.1

Quidel Corp Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

22 janv. 2026, 21:55 UTC

Résultats

Capital One Financial Posts Higher 4Q Profit As Lending Increases

22 janv. 2026, 23:52 UTC

Résultats

Intel Returns to Losses as Supply Shortages, Spending Weigh on Q4 Results and Forecast -- Update

22 janv. 2026, 23:48 UTC

Market Talk

Nikkei May Rise as Tensions Between U.S. and Europe Ease -- Market Talk

22 janv. 2026, 23:42 UTC

Market Talk

Gold Edges Lower on Possible Profit-Taking -- Market Talk

22 janv. 2026, 23:40 UTC

Market Talk

Spark NZ's Market Share Loss Concerns Bear -- Market Talk

22 janv. 2026, 23:30 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

22 janv. 2026, 23:30 UTC

Market Talk

Genesis Energy Can Beat Newly Upgraded Earnings Goal -- Market Talk

22 janv. 2026, 22:37 UTC

Market Talk
Acquisitions, Fusions, Rachats

Capital One CEO: Brex Buy Reflects Business Payments Focus -- Market Talk

22 janv. 2026, 21:59 UTC

Acquisitions, Fusions, Rachats

Capital One Strikes $5.15 Billion Deal for Fintech Brex -- Update

22 janv. 2026, 21:50 UTC

Market Talk
Acquisitions, Fusions, Rachats

Tech, Media & Telecom Roundup: Market Talk

22 janv. 2026, 21:44 UTC

Résultats

Self-Driving Stock Mobileye Plunged After Earnings. Here's Why. -- Barrons.com

22 janv. 2026, 21:32 UTC

Acquisitions, Fusions, Rachats

Capital One: Brex Invented Integrated Combination of Corporate Credit Cards, Spend Management Software and Banking in Single Platform >COF

22 janv. 2026, 21:31 UTC

Acquisitions, Fusions, Rachats

Capital One: Brex Is a Modern, AI-native Software Platform Offering Intelligent Finance Solutions >COF

22 janv. 2026, 21:31 UTC

Acquisitions, Fusions, Rachats

Capital One: Franceschi Will Continue to Lead Brex as Part of Capital One >COF

22 janv. 2026, 21:30 UTC

Acquisitions, Fusions, Rachats

Capital One to Acquire Brex in Combination of Stk and Cash Transaction Valued at $5.15 B >COF

22 janv. 2026, 21:30 UTC

Résultats

Intel Returns to Losses as Supply Shortages, Spending Weigh on Q4 Results -- WSJ

22 janv. 2026, 21:30 UTC

Acquisitions, Fusions, Rachats

Capital One To Acquire Brex >COF

22 janv. 2026, 21:13 UTC

Résultats

Intel Returns to Losses in Q4 as It Ramps Up Spending on Chip Production -- WSJ

22 janv. 2026, 21:11 UTC

Résultats

Intuitive Surgical Sees 2026 Impact From Tariffs 1.2% of Revenue, Plus or Minus 10 Basis Points >ISRG

22 janv. 2026, 21:11 UTC

Résultats

Intuitive Surgical Sees 2026 Adjusted Gross Profit Margin 67%-68% >ISRG

22 janv. 2026, 21:10 UTC

Résultats

Intuitive Surgical Sees 2026 Worldwide Da Vinci Procedure Growth of 13%-15% >ISRG

22 janv. 2026, 21:06 UTC

Résultats

Capital One 4Q Total Non-Interest Expense Increased 13% to $9.3B >COF

22 janv. 2026, 21:05 UTC

Résultats

Capital One 4Q Provision for Credit Losses Increased $4.1B >COF

22 janv. 2026, 21:05 UTC

Résultats

Capital One 4Q Rev $15.58B >COF

22 janv. 2026, 21:05 UTC

Résultats

Capital One 4Q EPS $3.26 >COF

22 janv. 2026, 21:05 UTC

Résultats

Capital One 4Q Net Interest Margin 8.26% >COF

22 janv. 2026, 21:05 UTC

Résultats

Capital One 4Q Net $2.13B >COF

22 janv. 2026, 21:05 UTC

Résultats

Capital One 4Q Adj EPS $3.86 >COF

22 janv. 2026, 21:05 UTC

Résultats

Capital One 4Q Net Charge-Offs $3.8B >COF

22 janv. 2026, 21:05 UTC

Résultats

Intuitive Surgical 4Q EPS $2.21 >ISRG

Comparaison

Variation de prix

Quidel Corp prévision

Objectif de Prix

By TipRanks

-3.13% baisse

Prévisions sur 12 Mois

Moyen 28.5 USD  -3.13%

Haut 35 USD

Bas 22 USD

Basé sur 5 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Neutre

5 ratings

1

Achat

3

Maintien

1

Vente

Éléments financiers

$

À Propos Quidel Corp

QuidelOrtho Corporation provides diagnostic testing solutions. The company operates through Labs, Transfusion Medicine, Point-of-Care, and Molecular Diagnostics business units. The Labs business unit provides clinical chemistry laboratory instruments and tests that measure target chemicals in bodily fluids for the evaluation of health and the clinical management of patients; immunoassay laboratory instruments and tests, which measure proteins as they act as antigens in the spread of disease, antibodies in the immune response spurred by disease, or markers of proper organ function and health; testing products to detect and monitor disease progression across a spectrum of therapeutic areas; and specialized diagnostic solutions. The Transfusion Medicine business unit offers immunohematology instruments and tests used for blood typing to ensure patient-donor compatibility in blood transfusions; and donor screening instruments and tests used for blood and plasma screening for infectious diseases. The Point-of-Care business unit provides instruments and tests to provide rapid results across a continuum of point-of-care settings. The Molecular Diagnostics business unit offers polymerase chain reaction thermocyclers; amplification systems; and sample-to-result molecular instruments and tests for syndromic infectious disease diagnostics. The company sells its products directly to end users through a direct sales force; and through a network of distributors for professional use in physician offices, hospitals, clinical laboratories, reference laboratories, urgent care clinics, universities, retail clinics, pharmacies, wellness screening centers, blood banks, and donor centers, as well as for individual, non-professional, and over-the-counter use. It operates in North America, Europe, the Middle East, Africa, China, and internationally. The company was incorporated in 1979 and is headquartered in San Diego, California.
help-icon Live chat